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Obesity is a global epidemic associated with multiple severe diseases. Several pharmacotherapies have
been investigated including the melanin concentrating hormone (MCH) and its receptor 1. The develop-
ment of MCHR1 antagonists are described with a speciﬁc perspective on different chemotypes investi-
gated in efforts to overcome hERG liabilities while having orally active, potent and selective
compounds with sufﬁcient brain penetration. A chemometric comparison of 2000 diverse MCHR1
and 1000 diverse hERG ligands underline the structural similarities. A binding pocket analysis of a
MCHR1 model and recent X-ray structures of GPCRs invoked in selectivity issues indicate a way to sup-
port future drug design.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Obesity is a chronic global epidemic disease subject to an
increasing prevalence.1 It affects a huge population, and in US more
than one-third of the adults (36%) are obese, that is, having a body
mass index (BMI) over 30 kg/m2, according to the most recent
National Health and Nutrition Examination Survey.2 Another
alarming ﬁgure from the same source is the high percentage (about
17%) of children and adolescents aged 2–19 years being obese.
Obesity should not be regarded only as a cosmetic problem as it
is a major contributor to the development of diseases such as type
2 diabetes mellitus, dyslipidemia, cardiovascular disease, stroke,
certain forms of cancer, osteoarthritis, and sleep apnea.1,2 Treat-
ments could involve dietary restrictions, exercise, surgery and
pharmacotherapy including modulation of central satiety and hun-
ger regulating systems, prevention of fat absorption, modulation of
fat metabolism or storage, and increase of thermogenesis.3
Melanin concentrating hormone (MCH) is an orexigenic cyclic
nonadeca-peptide, predominantly expressed in the lateral hypo-
thalamus and zona incerta, acting at the G-protein coupled recep-
tors (GPCRs) MCHR1 and MCHR2 widely expressed in the brain.4,5
The latter receptor is not expressed in rodents and accordingly less
characterized. MCH is an important mediator of energy homeosta-
sis,5,6 stimulating food intake in rats after intra cerebro-ventricular
(icv) injection,7 and increasing body weight.8(T. Högberg).
Y-NC-ND license.Transgenic mice over expressing the MCH gene are susceptible
to insulin resistance and obesity.9 On the other hand, MCH knock-
out mice are hypophagic, lean, and show an increased energy
expenditure.10 Consistent with this phenotype, transgenic mice
lacking the MCH receptor 1 maintain elevated metabolic rates
and remain lean despite hyperphagia that is counteracted by an
increased locomotion.11
The HTS derived small molecule antagonists T-226296 from
Takeda12 and SNAP-7941 from Synaptic13 (Fig. 1) provided the ﬁrst
pharmacological evidence of the therapeutic utility of MCHR1
antagonists in treatment of obesity. Besides, various CNS indica-
tions such as anxiety, depression, reward and sleep have also been
implicated for MCHR1 antagonists.6,13,14 Several excellent reviews
of literature and patents have described the developments.5,15 In
this account we make no attempt to repeat this information but
rather describe our own experiences from 7TM Pharma and Dr.
Reddy´s Laboratories while selecting representative examples of
compounds or development trends as illustration without any
attention to disregard other contributions. We will also provide a
chemogenetic analysis and a receptor comparison based on
recently disclosed X-ray structures (adrenergic b2, dopamine D3,
histamine H1, muscarinic M2, j-opioid and nociceptin receptors)
trying to describe why development of MCHR1 antagonists are
associated with issues relating to selectivity over certain aminergic
targets and hERG.
As mentioned, the ﬁrst chemical starting points of small mole-
cule antagonists were the biphenyl benzamides such as T-226296
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Figure 3. Urea linked derivatives from 7TM Pharma derived from T-226296.21
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Figure 4. Other examples of T-226296 derived compounds.
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Figure 5. Examples of benzamides24 inspired by T-226296 and physicogenically
related D2 receptor–ligands such as raclopride.23
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Figure 1. Early lead molecules providing mode of action.
6040 T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047(1a)12 followed by the disclosure of the dihydropyrimidone SNAP-
7941 (1b)13 having a unique eastern 4-piperidinylacetanilide. Since
then the ﬁeld has developed and ﬁve candidates shown in Figure 2
have been reported to have entered phase I clinical trials,5e,g that is,
GW856464 (2a),16 AMG-076 (2b),17 NGD-4715 (2c, structure assu-
med),3f,18 ALB-127158 (2d, structure assumed),19 and BMS-
830216, a prodrug of BMS-819881 (structure undisclosed).20
Especially the T-229296 chemotypes served as lead compounds
for many other companies including 7TM Pharma. Initially the tetr-
aline scaffold was used to explore alternative linkers and aryl sub-
stituents in the western part of the molecule in order to gain
general information of the SAR that would be used in the future de-
sign (Fig. 3).21 Ureas could serve as linkers but they were not com-
patible with biphenyl derivatives whereas biphenyl ethers
provided relatively potent compounds, for example, compound
3a having a binding afﬁnity of 10 nM and effect on food intake.21
More polar compounds could be achieved by replacement with
pyridyl (3b) or a triﬂuoromethoxy group on a tetralone (3c), but
with a 5-fold loss in potency.21 Other biarylcarboxamide variants
based on T-229296 with different tetraline isosters and amine sub-
stituents have been described by Takeda and several other compa-
nies (Fig. 4).5
Secondly, we used a methodology that has been developed to
ﬁnd physicogenetic relationships between GPCRs by comparing
the physicochemical nature of the 7TM binding pockets, which
indicated similarities to several monoaminergic receptors.22 We
focused on dopamine D2 and D3 receptor antagonists having intra-
molecular hydrogen bonded 2-methoxybenzamide systems, such
as raclopride (5a), comparable to the tetraline system in the Take-
da compounds (Fig. 5).23 This system also would allow for internal
masking of H-donor and H-acceptor sites in non-aqueous environ-
ments and promote passage over the blood–brain barrier while
providing open more soluble conformers in water.23,24 With mod-
eling support using a homology model of the MCH1 receptor, benz-
amides such as 5b (52 nM) and 5c (8 nM) were designed with more
lipophilic western parts required for binding to the MCHR1 in
accordance with the tetralines 3a–c.24 Extensive SAR work showedS
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Figure 2. Clinical development candidates.that coplanarity was needed for the benzamide part and that the
western urea hydrogen was most important. The compounds did
however display insufﬁcient PK properties and had some afﬁnity
for the serotonin 5HT2A and 5-HT2C, histamine H2 receptors and
the DA transporter which limited their usefulness.
Another important and early contribution came from the GSK
laboratories describing biphenyl carboxamides such as SB-
568849 (6a) derived from HTS hits.25 Thorough conformational
searches lead to a series of constrained analogues with favorable
properties, for example, 6b and the clinical candidate 2a.25 Many
other companies have made bicyclic analogues exempliﬁed in Fig-
ure 6.5 Notably, the fused benzene ring analogue 6cwas associated
with considerable partitioning into tissues and very high brain
penetration, but the corresponding thiophene derivatives such as
6d displayed reasonable volume of distribution and brain-to-plas-
ma ratios.26 NBI-845 produced a dose-dependent weight loss in a
rat DIO model at concentration levels not regarded to block the
hERG channel (patch-clamp 1.8 lM).
We used the QSAR information derived from about 300 benz-
amide structures, such as 5b and 5c, to construct four 3D pharma-
cophore models with individually optimized spatial features, that
is, hydrophobic, aromatic, hydrogen bond acceptor or donor sites
Figure 7. 3D pharmacophore used for in silico screening.27
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Figure 6. Other types of biaryl derivatives with GSK origin.
T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047 6041and a positive site (Fig. 7).The 3D pharmacophore models were
used for the virtual screening of about a million structures from
vendor libraries to produce 45 hits (7% hit rate of extracted sub-
set).27 Among the most potent antagonists found were quinolines
with cyclic amines in the 2-position exempliﬁed with 8a and 8b
in Figure 8. Argenta independently also identiﬁed such 2-amino-
quinolines as potent MCHR1 antagonists.28 We extensively
explored this chemotype and found that the distal aliphatic nitro-
gen, which was invoked in the pharmacophore models, was not
needed for the activity, for example, 8a and 8b both having binding
afﬁnities of 50 nM. Furthermore, an accurate Schild analysis
showed the oxymethylene amide 8e (3 nM) to be equipotent to
8c (5 nM) whereas 8d only having a distal aliphatic nitrogen was
over a 10-fold less active (76 nM).27 The 5-HT2C receptor was used
as counter screen target as this was judged to be the most interfer-
ing one but no liabilities were encountered. SAR and modelingN
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Figure 8. 2-Substituted quinoline virtual screening hits (8a–b) and further
optimized derivatives from 7TM Pharma.27studies showed that the quinoline nitrogen was the primary and
energetically more favored interaction point with AspIII:08
(192Asp rather than 123Asp is the preferred sequence annotation
including the signal peptide according to UniProt accession num-
ber Q99705) in the MCH receptor 1 rather than the distal nitrogen
in for example, 8c.27
These ﬁndings are in accordance with reports on isoelectronic
4-aminoquinolines from Merck (e.g., 9a) which subsequently were
modiﬁed into 2-aminoquinolines such as 9b that provided in vivo
proof of concept.29 Other 2-aminoquinolines, also originating from
screening hits, from Abbott exempliﬁed by 9c showed good
absorption in the brain of DIO mice (Fig. 9).30 In addition, we ex-
plored analogous quinazolines with reduced basicity compared to
quinolines to further suppress hERG interactions.31 We realized
this likely would lead to a loss in MCHR1 afﬁnity and optimizations
to compensate for this were required. An ensemble of homology
models taking the extracellular loops into account was developed
based on the recently published X-ray structure of the b2-adrener-
gic receptor to guide the design. The amide linker forms hydrogen
bonds to glutamine residues in TMIII, TMV and TMVI.31 Both qui-
nazoline nitrogens are engaged in interactions (N1 with 192AspI-
II:08 and N3 with272Thr in extracellular loop 2b). Quinolines such
as 8a–e only have the ionic interaction with AspIII:08 which could
explain the modest potency drop in the less basic quinazolines. The
new receptor model also support that the 4-methyl group provides
optimal van der Waals interactions in the corresponding quino-
lines.27,31 For the ﬁrst series of oxymethylene linked compounds
10a–b shown in Figure 10 the microsomal stability and hERG pro-
ﬁle were insufﬁcient.31 We turned to metabolically more stable
cinnamides instead and identiﬁed one optimized candidate 10c
that showed good efﬁcacy in a sub-chronic DIO study and a good
cardiovascular safety window in a dog study.31
Synaptic (presently Lundbeck) discovered the potent antagonist
SNAP-7941 (1b), which suffered from poor PK, which prompted
the search for other compounds having different western motifs
but retained the 3-(4-piperidinyl)acylanilide that seems to convey
unique MCHR1 binding features.32 Two optimized examples 11a–b
are given in Figure 11 showing the breath of diversity. Obviously
the anilinic moiety is a point of concern and initiatives to derisk
this group by introduction of ﬂuoro substituents (11a) were de-
scribed. It is interesting to note that combining sub-threshold
doses of the CB1 antagonist rimonabant and SNAP-94847 (11b)
produced a signiﬁcantly greater loss of body weight in DIO mice
compared with vehicle and monotherapies.33
In one line of our research we explored non-linear benzimid-
azole structures, intended to display lower propensity for tissue
association, appended with the 3-(4-piperidinyl)acylanilide sub-
structure (Fig. 12).34 We also explored some alternatives to the
acetanilide motif based on extensive modeling support. The
charged piperidine nitrogen of 12a forms an ion pair with AspIII:08
and the 3-benzimidazole nitrogen with AspVII:02 while the
remaining scaffold is engaged in favorable hydrophobic interac-
tions. The lactam 12c was found to be equipotent to 12a whereasN
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Institute.35,36
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Figure 12. Benzimidazoles derived from SNAP-7941 described by 7TM Pharma and
Dr. Reddy’s.34
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6042 T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047the imidazole 12b was inferior despite a predicted good docking
pose. The compounds such as 12a were very potent MCHR1 antag-
onists, however, also potent hERG channel blockers. In order to im-
prove upon this an extensive SAR work including reduction of
basicity, increasing polar surface area, lowering lipophilicity and
reducing ﬂexibility of linker chains in 12a was conducted. For
example compounds 12d and 12e both showed high potency with
signiﬁcant separation from hERG.34
Additional acetanilide MCHR1 antagonists have been reported,
for example, compound 13a depicted in Figure 13 displayed
1 nM binding afﬁnity but it also showed inhibition of the hERG
channel in patch-clamp assay with a comparable potency
(3 nM).35 On the other hand, the western motif could be modiﬁed
to a 4-arylphthalazin-1(2H)-one 13bwith retained MCHR1 binding
potency (1 nM) and a low hERG-binding activity (16 lM), but it
suffered from a poor PK proﬁle.36
Further continuation of SAR on T-226296 scaffold, Takeda iden-
tiﬁed compound 14a as a single digit nanomolar MCHR1 binder
which was equipotent on the 5-HT2c receptor (also involved in food
regulation).37 Replacing dihydronaphthalene with a quinolinemoiety as illustrated in Figure 14 led to compound 14b which
showed a comparable MCHR1 potency with a superior selectivity
over various transporters, enzymes and receptors including 5-
HT2c. However, it showed potent hERG inhibition (94% @ 10 lM)
in a patch-clamp study.38 Replacement of the terminal p-ﬂuoro-
phenyl group with a cyclopropylmethoxy group and increasing
bulk and polarity around the benzylic amine as in 14c led to potent
antagonism to MCHR1 (1.5 nM) with signiﬁcantly reduced hERG
inhibition (33% @ 10 lM). Compound 14c was orally bioavailable
and suppressed food intake in a DIO rat model.39
Screening of Merck sample collections against MCHR1 resulted
in the identiﬁcation of a reasonably potent spiro-piperidine 15a
also having a1A-adrenoceptor afﬁnity (Fig. 15). Maturation of this
hit led to 15b with subnanomolar MCHR1 afﬁnity and over 1000-
fold selectivity over a panel of 171 targets including a1A. Primary
issues associated with this compound were metabolic stability and
P-gp susceptibility. Hybridizing the structure with Synaptic’s com-
pound 11b provided the smaller and conformationally rigid 15c
which showed good MCHR1 afﬁnity (3.5 nM), but it was also a
potent binder to hERG. Replacement of the ether with an oxime
ether and the ﬂuoropyridyl with N-methylpyridone led to the opti-
mized candidate 15d having a single digit nanomolar MCHR1
activity with 1000-fold hERG separation and selectivity over a
large panel of targets. It had an attractive PK proﬁle with a brain-
to-plasma ratio of 0.43 in DIO mice and an appreciable free brain
concentration was found in rat CSF. In a sub-chronic DIO mice
study, it showed signiﬁcant reduction in body weight after once
daily oral treatment.40
Compound 6c (see above)26 displayed tissue partitioning and
this is a ﬁnding that has been reported by other groups such as
Abbott.41 One can envisage compounds having these stretched
amphiphilic structures with terminal amine functions (cationic
amphiphilic drugs) ﬁt into phospholipid membrane structures
and also be associated with phospholipidosis.42 A series with a
different Y-shaped topography has been described by Schering-
Plough43,44 which looks attractive with respect to a potentially
lower tissue association (Fig. 16). Once again the starting point
was a screening hit that was matured into compounds such as
16a. The series have shown interactions with the muscarinic M2
receptor but 16a was associated with a potent inhibition with
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T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047 6043the 5-HT uptake transporter, which could be eliminated by making
cyclic amines such as 16b which showed good effect in a DIO rat
study. However, the compounds contain the mutagenic 4-aminobi-
phenyl system that was eliminated by making bicycloalkyl isoster-
es such as 16c and optimizing the series based on receptor
occupancy studies, as potency and PK properties were not sufﬁ-
cient as predictors for in vivo efﬁcacy.44 Mixture Sciences identi-
ﬁed 16d from screening of combinatorial libraries as a potent
MCHR1 antagonist (IC50 6.1 nM) that showed no activity when
tested on a battery of receptors, enzymes and channels including
hERG. TPI 1361-17 inhibited MCH-induced food intake in dose-
dependent manner via i.c.v route.45
Beyond AMG-076 (2c), Amgen’s HTS campaign led to the iden-
tiﬁcation of the moderately potent MCHR1 antagonist 17a (Fig. 17).
However, this Y-shaped scaffold with the amine in a central posi-
tion was also associated with a comparable hERG-binding potency.
This hERG liability could be reduced by removing the western aryl
ring and incorporating polarity, for example, the alcohol 17b and
methyl sulfonamide 17c which differentiated MCHR1 potency
and hERG inhibition about 150-fold.46
Another series of compounds with a central amine functionality
exempliﬁed in Figure 18 originates from AstraZeneca.47 The HTS hit
18a was transformed into the drugable hit 18b displaying 29 nM
MCHR1 binding but also an appreciable hERG afﬁnity. Extensive
SAR exploration led to identiﬁcation of potent MCHR1 antagonists18c (35 nM) and 18d (2 nM) with signiﬁcant separation from func-
tional hERG inhibition (20.6 and >31.6 lM, respectively). However,
the modiﬁcations required to circumvent hERG-binding provided
ADME limitations hindering the progression of these molecules.47
Another route to circumvent hERG is to completely remove the
basic amine functionality even if hERG-binding have been reported
for such compounds.48 Thus, BMS has demonstrated several
non-basic compounds, inspired by the GSK compounds described
earlier, to be potent MCHR1 antagonists.49 Various prodrugs
(esters of glycine, alanine and phosphoric acid) were made to
improve solubility and exposure of these non-basic compounds
(Fig. 19). The free alcohols 19a and 19c have MCHR1 binding afﬁn-
ities of 10 and 18 nM, respectively.49 Rat PK studies of the prodrugs
19b and 19d at 10 mg/kg oral dose showed brain/plasma ratios of
0.9 and 2.5, respectively, of the corresponding alcohols. In an obese
Figure 20. PCA analysis of hERG ligands and MCHR1 antagonists extracted from a
cleaned ChEMBL dataset.50 The ﬁrst two principle components PC1 and PC2 are
shown. A: hERG ligands (blue). B: MCHR1 antagonists (dark) overlaid on the hERG
ligands. The numbers related to beige squares refer to representative MCHR1
compounds in the text. C: The distribution according to globularity.51,52 D:
Distribution according to molecular weight. For clarity we have eliminated nine
hERG ligands having PC1’s above four and molecular weight above 800 in the
graphs. Plots are created using ICM.63
6044 T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047rat model, compounds 19b and 19d showed 10.2% and 7.8% weight
loss, respectively, on day 29 after chronic treatment at a dose of 30
and 3 mg/kg orally.49
As illustrated above most chemotypes have been associated
with hERG liabilities and the structures have been subject to mod-
iﬁcations such as changing scaffold, targeting basicity, steric hin-
drance and polarity around the amine. By comparing a large
curated dataset of hERG channel blockers with MCHR1 antagonists
extracted from ChEMBL50 we explored these relationships further.
There are a total of 8869 compounds associated with hERG data in
ChEMBL of which 1783 structures are duplicates and 3707 com-
pounds lack sufﬁciently documented activity units. We also ex-
cluded 2300 of the remaining 3379 compounds having binding
activities >1 lM. Based on 2D ﬁngerprints from MOE (molecular
operating environment) software package,51 the remaining 1079
unique hERG nanomolar binding ligands were distributed on 326
clusters using a 0.7 similarity threshold, that is, the ligands repre-
sent a very diverse set of chemotypes. Likewise, of the 4207 com-
pounds associated MCHR1 data we removed 1333 duplicates, 618
less well documented compounds and 229 compounds with poten-
cies >1 lM. The remaining 2027 unique nanomolar binding
MCHR1 antagonists were distributed on 148 cluster using a 0.7
similarity threshold. A total of 833 (41%) compounds from this
dataset are within 0.7 similarity thresholds to any of the 1079 un-
ique hERG ligands. Thus, a considerable similarity on a substruc-
ture level exists between the two data sets supporting the
experimental ﬁndings described in this digest of most MCHR1
chemotypes being prone to hit hERG.
As a complement to the structural analysis abovewemade a PCA
analysis of the same data sets of MCHR1 and hERG ligands using 15
transparent physicochemical properties describing size, lipophilic-
ity, shape and polarity,52 calculated using the MOE software pack-
age.51 Figure 20A shows the data structure of the hERG ligands
using the ﬁrst two principal components PC1 and PC2 which de-
scribe 66% of the variance (an additional PC3 accounts for 75% of
the variance). Using the same parameters and PCs, the data struc-
ture of the MCHR1 dataset is superimposed on the hERG plot
(Fig. 20B). As can be seen most of the MCHR1 antagonists are over-
lapping with the hERG space which is in accordance with the inher-
ent difﬁculties to differentiate the afﬁnities for the two targets.
Figure 20C shows a color coding of the globularity of the associated
molecules and Figure 20D the molecular weight distribution.52 The
more elongated molecules are located in the northern parts of the
plots whereas Y-shaped and other more globular chemotypes in
the southern part (Fig. 20C). Likewise the higher molecular weight
molecules are located in the eastern part of the plots. Notably one
area in the northeastern part of the MCHR1 space is distinct from
the hERG space, but this region contains high molecular weight
stretched molecules violating Lipinski and similar drugability
indicators. For clarity and to link the analysis with the previous
discussions of various chemotypes, we have included the positions
for some representative compounds in Figure 20A and B.
Limiting the analysis to the ﬁrst two PCs (Fig. 20), it can be
noted that several chemotypes are located at the borders of the
hERG space, that is, 2a, 5c, 18d, 12e and 17b. Some of these com-
pounds are also reportedly devoid of hERG liabilities (such as 12e,
17b and 18d) or being a clinical candidate (2a). However, the other
clinical candidate 2b as well as other hERG-free compounds such
as 15d are in the midst of the hERG space which is in accordance
with the observations that changes in the scaffold or around the
amine can sometimes signiﬁcantly reduce hERG liability and these
differences are not captured by this model.48 Thus, 2b being an
amino acid and 15d carries a central oxime ether differentiating
over the related hERG-prone ether derivative 15c. A further reﬁned
Figure 21. Comparison of the binding pockets of the recently described MCHR131a with recent X-ray structures.53–62 A: Binding pocket alignments employing the
hydrophobicity scale in ICM.63 B: Binding pocket superposition of aminergic receptor–ligand complexes shown in C–I. The ligands are shown in yellow. C: MCHR1 (homology
model).31a D: b2AR.54 E: Nociceptin NOP.60 F: Dopamine D3.55 G: j-Opioid.57 H: Histamine H1.56 I: Muscarinic M2.61 Binding pocket properties are illustrated by the
interaction surface representing hydrophobic (green), acceptor (red) and donor (blue) regions. Illustrations are prepared using ICM.63
T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047 6045analysis using advanced classiﬁcation algorithms and chemical
descriptors associated with basicity, steric hindrance and local
polarities is beyond the scope of the present study.
Another challenge has been to achieve selectivity over various
aminergic receptors such as adrenergic, serotonergic, dopaminer-
gic, histaminergic, muscarinergic, opioid, neuropeptide Y and the
dopamine transporter. An increasing number of X-ray structuresof such receptors with bound ligands, that is, adrenergic b1AR/cya-
nopindolol (2VT4),53 b2AR/carazolol (2RH1),54 dopamine D3/eti-
clopride (3PBL),55 histamine H1/doxepin (3RZE),56 j-opioid/JDTic
(4DJH),57 l-opioid/morphinan antagonist (4DKL),58 d-opioid/nal-
trindole (4EJ4),59 nociceptin opioid (NOP)/peptide mimetic C-24
(4EA3),60 muscarinic M2/3-quinuclidinyl benzilate (3UON),61 and
muscarinic M3/tiotropium (4DAJ),62 have become available and
6046 T. Högberg et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6039–6047we have recently described the construction of a homology model
of MCHR1 based on the b2AR structure in complex with the ligand
10b.31a Comparison of this MCHR1 binding pocket model with the
ligand binding pockets of representative receptor–ligand com-
plexes, that is, b2AR (identical to b1AR), nociceptin NOP, dopa-
mine D3, j-opioid (identical to l and d), histamine H1 and
muscarinic M2 (identical to M3), are shown in Figure 21. Figure
21A illustrates the structural similarities of the orthosteric binding
pockets deﬁned by residue positions in contact with ligands in the
aminergic receptor structures. The topology and the arrangement
of the transmembrane helices in the aminergic X-ray structures
are surprisingly similar and the backbone RMSD variation between
the binding pocket residues is between 0.3 and 1.1 Å, when com-
paring the different receptors against each other. Based on align-
ment and amino acid similarity of binding pocket residues (
Fig. 21A) the closest related binding pocket receptor to MCHR1 is
the recently solved nociceptin opioid receptor followed by j/l/d
opioid, b1AR/b2AR, and dopamine D3, whereas histamine H1 and
muscarinic M2/M3 are more distant (Fig. 21C–I). While the noci-
ceptin opioid, j-opioid, b2AR, and the dopamine D3 receptor ap-
pear to have similar binding pocket properties with respect to
size, shape and ligand accessibility, the shape of the histamine
H1 and especially the muscarinic M2 receptor, where a layer of
tyrosine residues form an aromatic cap restricting dissociation of
the bound ligand, appear to be different compared to the other
structures. Given the conserved topology of the transmembrane
helices in the aminergic receptor family and the availability of clo-
sely related template structures for MCHR1 homology modeling,
incorporation of biochemical and (Q)SAR data, in combination with
continuous improvement of molecular modeling and docking algo-
rithms complemented by advances in computing technologies de-
liver great possibilities to predict MCHR1–ligand complexes. This
could provide future researchers with valuable information about
molecular interactions with accuracy approaching an experimental
structure. In silico screening efforts based on such models in com-
bination with advanced classiﬁcation methods trained to discrim-
inate hERG binders from non-binders based on the large number of
diverse compounds associated with hERG data, in brief presented
above, could assist the design and optimization of novel hERG-free
selective MCHR1 antagonists.
Beyond the common challenges in drug design related to ADME
and safety proﬁles, cardiovascular risk involving hERG-binding
activity and drug induced QTc prolongation has been a major hur-
dle for a signiﬁcant number of MCHR1 research programs.47,48 It is
very clear that the structural and physicochemical requirements
for MCHR1 potency and hERG inhibition usually correlate with
each another as supported by our chemogenomic analysis de-
scribed above. The design elements addressing the hERG issue
have led to compounds that are either devoid of in vivo activity
or unsuitable for clinical development on the basis of their overall
ADME and safety proﬁles. Despite enormous efforts over a decade,
only ﬁve molecules have entered Phase I clinical trials. Except
BMS-830216, all other four compounds GW856464 (2a),
AMG-076 (2b), NGD-4715 (2c) and ALB-127158 (2d) have been
discontinued for further clinical development though signiﬁcant
structural differences exist amongst these candidates. BMS has
completed a randomized, double-blind, placebo-controlled,
ascending multiple-dose and parallel arm study to evaluate the
safety, pharmacokinetics and pharmacodynamics of BMS-830216
(prodrug of BMS-819881) in obese subjects.64 Further progression
of this program would demonstrate the developability of MCHR1
antagonists as anti-obesity therapy. Our initial structural analysis
and comparison between MCHR1 and recent aminergic receptor-
ligand complexes may inspire the search for improved molecules
utilizing this information in combination with more sophisticated
hERG ﬁlters.Acknowledgments
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